Do we know the minimal clinically important difference (MCID) for COPD exacerbations

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 2, 2013, Pages 243-249

  Chapman, Kenneth R ^a,b   Bergeron, Celine ^c   Bhutani, Mohit ^d   Bourbeau, Jean ^e   Grossman, Ronald F ^b   Hernandez, Paul ^f   McIvor, R Andrew ^g   Mayers, Irvin ^d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Clinical epidemiology; COPD; Exacerbation; MCID; Outcomes

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; PLACEBO; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSENSUS; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART FAILURE; HUMAN; LOW DRUG DOSE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RELIABILITY; REVIEW; STATISTICAL SIGNIFICANCE; VALIDITY;

DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 84875837001     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.733463     Document Type: Review

References (50)

1. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32-38
2. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-907.
3. Pizzichini E, Pizzichini MMM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements. Amer J Respir Crit Care Med 1996; 154:308-317.
4. Horvath I, Donnelly LE, Kiss A, et al. Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Amer J Respir Crit Care Med 1998; 158:1042-1046.
5. Chapman KR, Verbeek PR, White JG, Rebuck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. New Engl J Med 1991; 324:788-794.
6. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31:320-325.
7. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallelgroup controlled trial. J Allergy Clin Immunol 1992; 90:32-42
8. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
9. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832-840.
10. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760-765.
11. Health Indicators 2008. Canadian Institutes for Health Research, 2008. (Accessed 25 March 2012).
12. Spencer S, Jones PW, Globe SG. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58:589-593.
13. Chang CL, Sullivan GD, Karalus NC, Hancox RJ, McLachlan JD, Mills GD. Audit of acute admissions of chronic obstructive pulmonary disease: inpatient management and outcome. Intern Med J 2007; 37:236-241.
14. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors aff ecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26:234-241.
15. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
16. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852.
17. Calverley PM. Minimal clinically important difference-exacerbations of COPD. COPD 2005; 2:143-148.
18. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416-469.
19. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40:171-178.
20. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
21. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371-383.
22. Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. Health Qual Life Outcomes 2006; 4:62.
23. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol: 1998; 16:139-44.
24. Norman GR. The relation between the minimally important difference and patient benefit. COPD 2005; 2:69-73.
25. de Vet HC, Terwee CB, Ostelo RW, Beckerman H, Knol DL, Bouter LM. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes 2006; 4:54-58.
26. Gatchel RJ, Mayer TG. Testing minimal clinically important difference: additional comments and scientific reality testing. Spine J 2010; 10:330-332.
27. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2:75-79.
28. Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003; 56:1170-1176.
29. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. AmJ Respir Crit Care Med 2008; 177:396-401.
30. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:842-846.
31. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New Engl J Med 2011; 364:1093-1103.
32. Petty TL. The combination of ipratropium and albuterol is more eff ective than either agent alone. Chest 1995; 107 Suppl.: 183S-186S.
33. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Inter Med 2007; 146:545-555.
34. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J: 2008; 31:927-933.
35. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63:122-128.
36. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374:685-694.
37. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009; 4:245-251.
38. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebocontrolled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11:603-610.
39. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
40. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10:815-821.
41. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058-1069.
42. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182:155-162.
43. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJG, Dutch Tiotropium SG. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55:289-294.
44. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
45. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224.
46. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
47. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320:1297-1303.
48. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
49. Calverley PMA, Spencer S, Willits L, Burge PS, Jones PW, Isolde SG. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124:1350-1356.
50. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.